Available Technologies

Browse Penn-owned technologies available for licensing.


Device for MRI scanner intra-bore disinfection


With the advent of COVID-19, renewed emphasis has been placed on disinfecting surfaces in the medical environment. Disinfecting the MRI scanner bore is of particular importance due to the substantial time the patient spends in the bore, the close contact between the patient and the bore, and continuous patient turnover. The scanner bore presents a significant challenge to disinfect due to the strong magnet field and the space constraints imposed by the bore size and geometry. Also, for maximum effectiveness at controlling pathogen spread, disinfection of the bore must occur between each patient without disrupting the MRI schedule.

Current method of disinfecting the bore involves the use of harsh chemicals manually applied by the MRI technician, which is inconsistent, time-consuming, and challenging to perform between patients due to scheduling constraints and MRI technician’s patient responsibilities. Additionally, the harsh chemical residues and fumes produced by the current method can corrode sensitive electronic systems as well as affect some patients.


To address the limitations of the current manual method of MRI bore disinfection, a device was developed that can rapidly and effectively disinfect this area using UV-C light.

The device is specifically designed to use non-ferrous materials and shielding of the electronic components to eliminate magnetic field interference. The system produces an intensity of UV-C which disinfects the entire MRI bore within minutes, enables rapid setup and removal, eliminates the use of harsh chemicals, minimizes the MRI technician involvement, and provides the capability to rapidly and effectively disinfect the MRI bore between patients.


  • Magnetic field safe
  • Rapid and effective disinfection
  • Easy set up and operation
  • Small size
  • Low cost


Disinfection of bore for MRI and other types of scanners (CT, PET, PET-MR, SPECT)


Stage of Development: 

  • Built prototype
  • Confirmed effectiveness

Intellectual Property: 

Provisional application pending

Desired Partnerships: 

  • License
  • Co-development

Patent Information:


Norman Butler
James Pilla
Terence Gade
Gabor Mizsei

Docket # 20-9379

For Information, Contact:

Linara Axanova
Associate Director, PSOM Licensing Group
University of Pennsylvania


Infectious Disease